<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chang W</submitter><funding>Shanghai Municipal Health and Family Planning Commission</funding><funding>Shanghai Public Health System Construction Three-Year Action Plan</funding><funding>National Natural Science Foundation of China</funding><pagination>140</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10230736</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>&lt;h4>Background and aims&lt;/h4>This study aimed to investigate the expression of plasma versican and plasma exosomal versican in non-small cell lung cancer (NSCLC) and its correlation with clinicopathological features, and to evaluate its diagnostic performance in NSCLC and its predictive function for NSCLC incidence and metastasis risk.&lt;h4>Materials and methods&lt;/h4>There were 110 instances of NSCLC, 42 cases of benign lung disease, and 55 healthy controls from September 2018 to October 2020 at Tongji Hospital Affiliated to Tongji University. Blood was collected and plasma was separated before surgery, and plasma exosomes were extracted by ExoQuick kit. Morphological and molecular phenotype identification of exosomes was performed by transmission electron microscopy, Nanosight particle tracki</pubmed_abstract><journal>Respiratory research</journal><pubmed_title>Plasma versican and plasma exosomal versican as potential diagnostic markers for non-small cell lung cancer.</pubmed_title><pmcid>PMC10230736</pmcid><funding_grant_id>20204Y0070</funding_grant_id><funding_grant_id>81902984, 81974314, 82072362, 82002223</funding_grant_id><funding_grant_id>GWV-10.1-XK04</funding_grant_id><pubmed_authors>Shang A</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Li D</pubmed_authors><pubmed_authors>Yang D</pubmed_authors><pubmed_authors>Sun Z</pubmed_authors><pubmed_authors>Chang W</pubmed_authors><pubmed_authors>Quan W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Plasma versican and plasma exosomal versican as potential diagnostic markers for non-small cell lung cancer.</name><description>&lt;h4>Background and aims&lt;/h4>This study aimed to investigate the expression of plasma versican and plasma exosomal versican in non-small cell lung cancer (NSCLC) and its correlation with clinicopathological features, and to evaluate its diagnostic performance in NSCLC and its predictive function for NSCLC incidence and metastasis risk.&lt;h4>Materials and methods&lt;/h4>There were 110 instances of NSCLC, 42 cases of benign lung disease, and 55 healthy controls from September 2018 to October 2020 at Tongji Hospital Affiliated to Tongji University. Blood was collected and plasma was separated before surgery, and plasma exosomes were extracted by ExoQuick kit. Morphological and molecular phenotype identification of exosomes was performed by transmission electron microscopy, Nanosight particle tracki</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-21T21:56:26.546Z</modification><creation>2025-04-21T21:56:26.546Z</creation></dates><accession>S-EPMC10230736</accession><cross_references><pubmed>37259101</pubmed><doi>10.1186/s12931-023-02423-4</doi></cross_references></HashMap>